A082304 / S2402 — Perioperative versus adjuvant systemic therapy in resectable non-small cell lung cancer (PROSPECT-Lung)

Phase 3 · Non-Small Cell Lung Cancer

Population

Stage II-IIIB resectable non-small cell lung cancer.

Primary Endpoint

Overall survival

Rationale

Both perioperative and adjuvant chemo-immunotherapy improve outcomes in resectable NSCLC, but they have never been compared head-to-head, leaving clinicians unsure whether giving immunotherapy before surgery adds value over an adjuvant-only approach.

What It Could Change

Would directly answer whether neoadjuvant plus adjuvant immunotherapy is worth the added complexity versus adjuvant therapy alone in resectable NSCLC.